Rocket Pharma is getting ready to light up national landmarks on Thursday as part of its annual rare disease awareness effort, but this year the event is even more meaningful as Rocket awaits an FDA decision on its first drug candidate.

Rocket’s gene therapy candidate, Kresladi, to treat severe leukocyte adhesion deficiency-I (LAD-I) is being considered under priority review with a June 30 decision date. Rocket also plans to submit another biologics license application (BLA) in the first half of the year for RP-L102 treatment for fanconi anemia.

“For Rocket we focused from day one starting the company to do something for the rare disease patient and community before we have therapies in the clinic,” said Rocket president and chief operating officer Kinnari Patel.

Along with the Empire State Building in New York, where Rocket has offices, the FDA headquarters, Niagara Falls, and NASDAQ are among the more than 100 places around the world that will light up in the green, blue, pink and purple colors that represent rare disease. Rocket first began the illumination campaign in 2019, although the National Organization for Rare Disease (NORD) took over more recently.

Meanwhile, Rocket also is planning a day of panel discussions and events on Thursday, as well as a media push, to draw attention to rare diseases, which in total affect 10% of people in the US. Themes for the day center on patient support, patient advocacy and genetic testing, Patel said.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.